Janssen Norway’s Mario Klesse shares his first impressions of the Norwegian pharma market, his strategic priorities for the affiliate, how Janssen is defining and meeting unmet patient needs, key access challenges, and the importance of bringing more clinical trials to Norway.
We will only see the massive advantages of individualised medicine in Norway when we really change the system
Sissel Lønning Andresen explains how Pfizer Norway has been a pioneer of digital communication channels for years, what other Pfizer affiliates can learn from Norway in this field, and how…
Roche Diagnostics Norway’s Daniel Malarek discusses the resurgence of diagnostics in the wake of the COVID-19 pandemic, the Norwegian approval process for diagnostic tools, and the importance of stakeholder education.…
Filip Standaert outlines the significance of the Nordic cluster to J&J’s medical device operations in Europe, how the affiliate responded to the COVID-19 crisis, and the ways in which J&J…
Norway has been a global frontrunner in collecting health data and building unique registries for decades but has struggled to utilise and benefit from them. Karita Bekkemellem, CEO of the…
The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with a yawning gap still existing between vaccination rates in developed and developing economies and…
Equality has long been a deeply held ideal in Norway, where the concept of allemannsretten – the legal right to roam – permeates all aspects of society. Notably, surplus wealth…
See our Cookie Privacy Policy Here